Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02133924
Recruitment Status : Recruiting
First Posted : May 8, 2014
Last Update Posted : November 12, 2020
Sponsor:
Collaborator:
Biogen
Information provided by (Responsible Party):
John Levine, Icahn School of Medicine at Mount Sinai

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2022